Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

FDA accepts NDA resubmission for sodium zirconium cyclosilicate

Oct. 18, 2016

Omeros reports phase II data for OMS-721, pursuing FDA breakthrough therapy designation

Oct. 18, 2016

Phase II results lead NeuroVive to discontinue development of CicloMulsion for acute kidney injury

Oct. 13, 2016

Takeda Pharmaceutical presents EIT6 inhibitors

Oct. 13, 2016

Xenetic Biosciences reports positive data from phase II trial of erepoxen

Oct. 11, 2016

JW Pharmaceutical reports desfesoterodine derivatives

Oct. 10, 2016

Toray Industries prepares and tests agents for urinary incontinence

Oct. 6, 2016

FDA grants orphan drug designation to AbbVie's atrasentan

Oct. 5, 2016

Dimerix reports positive safety data for phase II trial of DMX-200

Oct. 5, 2016

twoXAR collaborates with Mount Sinai researchers in diabetic nephropathy

Oct. 5, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
K2 nabs two Antengene bispecific TCEs in $2B license, option deal
BioWorld
MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene...
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...